WO2014040396A1 - 一种调节免疫的中药组合物及其制备方法 - Google Patents

一种调节免疫的中药组合物及其制备方法 Download PDF

Info

Publication number
WO2014040396A1
WO2014040396A1 PCT/CN2013/001113 CN2013001113W WO2014040396A1 WO 2014040396 A1 WO2014040396 A1 WO 2014040396A1 CN 2013001113 W CN2013001113 W CN 2013001113W WO 2014040396 A1 WO2014040396 A1 WO 2014040396A1
Authority
WO
WIPO (PCT)
Prior art keywords
chinese medicine
traditional chinese
medicine composition
parts
composition according
Prior art date
Application number
PCT/CN2013/001113
Other languages
English (en)
French (fr)
Inventor
钟虹光
易敏之
卢建中
Original Assignee
江中药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江中药业股份有限公司 filed Critical 江中药业股份有限公司
Priority to JP2015531424A priority Critical patent/JP6305407B2/ja
Priority to IN2833DEN2015 priority patent/IN2015DN02833A/en
Priority to RU2015113319A priority patent/RU2630056C2/ru
Priority to EP13837349.3A priority patent/EP2949334B1/en
Priority to US14/428,313 priority patent/US9775868B2/en
Priority to EP19175214.6A priority patent/EP3560507B1/en
Priority to KR1020157008510A priority patent/KR101908381B1/ko
Publication of WO2014040396A1 publication Critical patent/WO2014040396A1/zh
Priority to ZA2015/02271A priority patent/ZA201502271B/en
Priority to US15/698,572 priority patent/US10537600B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/074Ganoderma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/066Clavicipitaceae
    • A61K36/068Cordyceps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738Rosa (rose)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964Anemarrhena
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/344Codonopsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/36Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn

Definitions

  • the invention relates to a traditional Chinese medicine composition for regulating immunity and a preparation method thereof.
  • the immune system is the defensive structure that the body protects itself, and plays an important role in the occurrence, development and prevention of diseases.
  • Modern immunology believes that the body's immune function has three major functions: defensive infection, self-stability and immune surveillance. Under normal circumstances, the body maintains a balanced state, and relies on immune function to resist various infections and eliminate harmful substances in the body, that is, “self.” Identify “, "exclude dissidents” and achieve their own stable physiological protection.
  • the immune function is abnormal, its own homeostasis will be broken, leading to a variety of autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, scleroderma, Behcet's disease, AIDS and other diseases. And it is closely related to the occurrence of diseases such as cancer, hypertension and diabetes.
  • Chinese medicine believes that the occurrence, development and outcome of the disease depends on the growth and decline of the righteousness and evil, and is closely related to the immune function of the body, thus proposing the main principles of healing the disease.
  • Traditional Chinese medicines are mostly natural medicines, which have mild medicinal properties and few adverse reactions. They have unique pharmacological effects in coordinating the overall balance of the body and enhancing the body's disease resistance.
  • Modern scientific research proves that more than 200 kinds of traditional Chinese medicines such as ginseng, astragalus, ganoderma lucidum, medlar, radix isatidis and honeysuckle have good immune regulation and can regulate all aspects of immune function.
  • the traditional Chinese medicine composition (containing American ginseng, ganoderma lucidum, fermented Cordyceps powder, rose flower, Zhimu, lily and the like) is formed on the basis of clinical experience, combined with modern research results, and optimized by clinical and experimental research. With qi and nourishing yin, Yishen Bufei, qi and phlegm, clearing away heat and lungs, stagnation and strengthening the right, regulating immunity.
  • the object of the present invention is to provide a traditional Chinese medicine composition for regulating immunity and a preparation method thereof, which have the effects of tonifying qi and nourishing yin, replenishing kidney and nourishing lung, regulating qi and dissipating phlegm, clearing away heat and moistening lungs, eliminating evil and strengthening righteousness, regulating immunity, and being suitable for prevention and treatment.
  • Allergic diseases include allergic rhinitis, allergic asthma, atopic dermatitis, urticaria, viral diseases including hepatitis B, AIDS, and can increase white blood cells, prevent radiation damage, slow down the side effects caused by chemotherapy, and improve Male sexual function.
  • a traditional Chinese medicine composition for regulating immunity which is characterized by the rule of Chinese medicine "supporting righteousness and evil spirits", Fang Zhongjun medicine American ginseng tastes bitter, slightly sweet, cold, has the effect of nourishing qi and nourishing yin, clearing fire and fluid.
  • Modern research shows that American ginseng has a wide range of biological activities.
  • the main active ingredients are American ginseng polysaccharides, saponins and other compounds and trace elements, which can act on A variety of immune-active cells promote the secretion of certain cytokines to further exert immunomodulatory effects. It has obvious protective effect on immunosuppression caused by immunosuppressive agents, and thus can effectively and effectively treat patients with clinical tumor radiotherapy, chronic radiation sickness patients and various causes of immunocompromised patients.
  • the American ginseng can significantly prolong the weight-bearing swimming time of mice, improve the exercise tolerance of mice, and have a dose-response relationship.
  • the liver glycogen consumption of mice after exercise can be significantly reduced, which can increase liver glycogen storage and maintain blood sugar levels during exercise.
  • Reduce the lactic acid content improve the aerobic metabolism of mice, so that the lactic acid produced during the glycolysis does not easily accumulate in the muscles, thus delaying the production of fatigue; reducing the serum urea nitrogen content during exercise, can make the body load Increased adaptability and accelerate the elimination of fatigue.
  • the main effect is that Ganoderma lucidum polysaccharides play a potent effect.
  • Ganoderma lucidum polysaccharide can significantly enhance the body's immune function, such as enhancing delayed allergic reaction in mice, promoting lymphocyte proliferation, enhancing cytotoxic cell function, enhancing macrophage phagocytosis, enhancing NK cell cytotoxic activity and promoting cytokine production. .
  • Ganoderma lucidum polysaccharides also have the effect of resisting fatigue and improving the body's ability to move. After ganoderma lucidum polysaccharides were administered to mice, the mice's exhaustive swimming time and hypoxia tolerance time were significantly prolonged, the liver glycogen level was increased, and the blood lactate and blood urea nitrogen levels were reduced after high-intensity quantitative load exercise.
  • Cordyceps sinensis is sweet and warm, has the effect of nourishing kidney and nourishing the lungs, stopping bleeding and removing phlegm.
  • Modern research on Cordyceps sinensis plays an important role in enhancing the immune function of the body, and can significantly increase the quality of thymus and spleen after dexamethasone immunosuppressive effect. Improve the role of the organ index and protect against immune liver damage.
  • Cordyceps mycelium and its fruiting body extract can enhance the body's immune regulation function: promote the proliferation of T and B lymphocytes, reduce delayed type hypersensitivity induced by alloantigen antigens and mixed lymphocyte reaction, anti-leukosis Lewis lung cancer , anti-radiation damage, activate the mononuclear-macrophage system and improve the body's immune function, especially the level of humoral immunity.
  • Cordyceps water extract can promote the proliferation of immune cells.
  • Cordyceps fermentation broth has similar functions in the body immune regulation function as wild Cordyceps fruit body and artificial cordyceps mycelium.
  • Zuozhi medicine rose Zhimu Liqi Huayu, Ziyin Runzao, Qixie Fuzheng, helper medicine anti-inflammatory and regulate immunity, among which rose is sweet, slightly bitter, warm, with qi and qi, and blood
  • the effect of dispersing, modern pharmacological research shows that the pharmacological effects of roses are extensive, especially in the treatment of cardiovascular diseases, immune inflammation and anti-tumor, anti-oxidation, choleretic, detoxification and so on.
  • the mother-inducing taste is bitter, sweet and cold. It has the effects of clearing away heat and purging fire, nourishing yin and moistening dryness.
  • Zhimu has anti-inflammatory, anti-oxidation, anti-virus, anti-tumor and immune regulation effects, among which active ingredient mango Glycoside can increase the number of aging red blood cells.
  • Aging red blood cells can increase the secretion level of IL-2 in T lymphocytes and increase the immune level of the body, which is similar to the effect of erythrocyte-enhanced lymphocyte factor secretion. This effect may be related to the anti-lipid peroxidation and stable erythrocyte membrane receptor activity of mangiferin.
  • the qi in the above traditional Chinese medicine composition can be replaced by the same kind of supplement.
  • the addition of Ganoderma lucidum spore powder and Ganoderma lucidum nut oil to the traditional Chinese medicine composition can improve the immunomodulatory effect of Ganoderma lucidum.
  • the invention relates to a traditional Chinese medicine composition for regulating immunity, which comprises the following raw materials and weight ratio preparation: 1 ⁇ 100 parts of American ginseng, 1 ⁇ 100 parts of Ganoderma lucidum, 60 parts of fermented Cordyceps powder, 1 ⁇ 60 parts of rose flower , Zhimu 1 ⁇ 60 copies.
  • the traditional Chinese medicine composition as described above is characterized in that the weight ratio of the raw materials is: 10 to 90 parts of American ginseng, 10 to 90 parts of Ganoderma lucidum, 5 to 50 parts of fermented Cordyceps powder, 5 to 50 parts of rose, and 5 to 50 parts of Zhimu 50 copies.
  • the traditional Chinese medicine composition as described above is characterized in that the weight ratio of the raw materials is: 30 parts of American ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 25 parts of rose, and 16 parts of Zhimu.
  • the traditional Chinese medicine composition as described above is characterized in that 10 to 50 parts of lily or a lily extract prepared by a conventional method of medicinal method is added to the raw material ratio to enhance the fatigue resistance thereof.
  • Anti-hypoxia, anti-tumor and immune regulation Lily is sweet and slightly cold, with the effect of moistening the lungs and relieving cough, clearing the heart and calming the nerves.
  • Modern pharmacological research shows that lily has anti-fatigue, anti-hypoxia, anti-tumor and immune regulation, and its active ingredient lily polysaccharide has many physiological functions. : 1 Anti-oxidation and anti-fatigue function.
  • Lily crude polysaccharide has anti-oxidation effect, which can increase the activity of SOD, catalase and glutathione in the blood of aging mice caused by D-galactose. 2 Eliminate free radicals and anti-aging functions. Compared with the ability of common antioxidants (thiourea, ascorbic acid, benzoic acid, etc.) to scavenge hydroxyl radicals, the removal effect of Baihe extract is significantly better. 3 improve immunity and anti-tumor effects. Lily polysaccharide can enhance the non-specific and specific immune function of immunosuppressed mice. 4 hypoglycemic effect. Lily polysaccharide has obvious hypoglycemic effect on mice induced by alloxan.
  • the traditional Chinese medicine composition as described above characterized in that the American ginseng can be replaced by any one of adult ginseng, codonopsis pilosula, ginseng ginseng or scutellaria, or any one of ginseng extract, codonopsis extract, ginseng extract or scutellaria extract.
  • the fermented Cordyceps powder can be replaced with Cordyceps sinensis or Cordyceps extract.
  • the traditional Chinese medicine composition as described above is characterized in that 10 to 50 parts of ganoderma lucidum spore powder and or ganoderma lucidum spore oil are further added to the raw material ratio.
  • the traditional Chinese medicine composition as described above is characterized in that the fermented Cordyceps powder is prepared by biological fermentation, and the strains of the fermented Cordyceps powder include Paecilomyces battus, bat moth, sphaeroides, leucocystis, Mortierella fungus, ergot fungus fungus Cordyceps sinensis or C. sinensis.
  • the traditional Chinese medicine composition as described above characterized in that the source of the raw material may be a Chinese medicinal material or an extract prepared by a conventional method, such as American ginseng extract, ganoderma lucidum extract, rose extract, which is equivalent to the crude drug amount of the traditional Chinese medicinal material. Extract, Zhimu extract, lily extract.
  • the traditional Chinese medicine composition as described above characterized in that the raw material may be an effective part corresponding to the extraction of the crude drug amount of the Chinese medicinal material, such as American ginseng saponin and or American ginseng polysaccharide, Ganoderma lucidum polysaccharide and or Ganoderma lucidum triterpenoid compound, Cordyceps polysaccharide and Cordyceps sinensis. Amino acids, rose flavonoids and or rose oil, timosaponin and or mangiferin.
  • the Chinese medicinal material such as American ginseng saponin and or American ginseng polysaccharide, Ganoderma lucidum polysaccharide and or Ganoderma lucidum triterpenoid compound, Cordyceps polysaccharide and Cordyceps sinensis.
  • the medicinal materials are taken separately, the volatile oil is extracted from the rose, and the distilled aqueous solution is collected and used; the American ginseng and the kiln are added with 60 ⁇ 80% ethanol for 2 times, and combined.
  • Ethanol solution filtered, the filtrate is recovered from ethanol and concentrated to a concentration of 1.10 ⁇ 1.15 in a concentration of 60 ° C; Ganoderma lucidum, fermented Cordyceps powder and rose medicinal residue and American ginseng, Zhimu drug residue mixed, add 6 to 12 times Dilute water 2 ⁇ 3 times, combine the decoction with the above aqueous solution, filter, and concentrate the filtrate to 60 ° C relative density 1.15 ⁇ 1.20, mix with the above concentrate, granulate, dry, spray the rose volatile oil evenly In the granules, mix and prepare the finished dosage form.
  • the medicinal materials are respectively taken, the volatile oil is extracted from the rose, and the aqueous solution after the distillation is collected, and the dregs and the ganoderma lucidum and the fermented Cordyceps powder are added 6 to 12 times.
  • the water is boiled twice, and the decoction and the above aqueous solution are combined, filtered, and the filtrate is concentrated to a relative density of 1.15 to 1.20 at 60 ° C.
  • the extract of American ginseng is equal to the prescribed amount, and the extract of Zhimu is mixed, granulated, and dried.
  • the rose volatile oil is evenly sprayed into the granules and mixed to prepare a finished dosage form.
  • the preparation method of the traditional Chinese medicine composition as described above is characterized in that the finished dosage form can be any dosage form prepared by a conventional pharmacy process using a pharmaceutically acceptable carrier or excipient.
  • the traditional Chinese medicine composition as described above is characterized in that it is used for the preparation of a health food or medicine for preventing and treating allergic diseases, including allergic rhinitis, allergic asthma, atopic dermatitis, and urticaria.
  • the traditional Chinese medicine composition as described above is characterized in that it is used for the preparation of a health food or medicine for preventing and treating a viral disease, wherein the viral diseases include hepatitis B and AIDS.
  • the traditional Chinese medicine composition as described above is characterized by the use in the preparation of a health food or medicine having an effect of increasing white blood cells.
  • the traditional Chinese medicine composition as described above is characterized by the use in the preparation of a health food or medicine having radiation damage prevention.
  • the traditional Chinese medicine composition as described above is characterized in that it is used in the preparation of a health food or medicine for alleviating toxic side effects caused by radiotherapy and chemotherapy.
  • the traditional Chinese medicine composition as described above is characterized by the use in the preparation of a health food or medicine for improving male sexual function.
  • the traditional Chinese medicine composition as described above is characterized by the use in the preparation of a health food or medicine for enhancing the immune function of the human body.
  • the traditional Chinese medicine composition as described above is characterized by the preparation of a health food or medicine for relieving physical fatigue.
  • the invention has the advantages of providing a traditional Chinese medicine composition for regulating immunity and a preparation method thereof, and the utility model has the functions of tonifying qi and nourishing yin, replenishing kidney and nourishing lung, regulating qi and dissipating phlegm, clearing heat and moistening lung, eliminating phlegm and strengthening righteousness, regulating immunity, and being suitable for prevention and treatment
  • Allergic diseases include allergic rhinitis, allergic asthma, atopic dermatitis, urticaria, viral diseases including hepatitis B, AIDS, and can increase white blood cells, relieve fatigue, prevent radiation damage, and reduce the side effects caused by chemotherapy. It can also improve male sexual function.
  • the present invention regulates immunity and anti-allergy research. Experiment 1 Study on immunomodulatory effects of the present invention
  • the traditional Chinese medicine composition (American ginseng, Ganoderma lucidum, fermented Cordyceps powder, rose flower, Zhimu) takes rose flower to extract volatile oil, and the aqueous solution after steaming is collected, and used; American ginseng, Zhimu plus 60 ⁇ 80% ethanol extraction 2 Then, the ethanol solution is combined, filtered, and the filtrate is recovered and concentrated to 60 ⁇ concentrated solution with a relative density of 1.10 ⁇ 1.15; Ganoderma lucidum, fermented Cordyceps powder and rose medicinal residue, and American ginseng and Zhimu drug residue are mixed, and 6 ⁇ 12 is added.
  • Dilute water 2 ⁇ 3 times combine the decoction with the above aqueous solution, filter, concentrate the filtrate to 60 ° C relative density 1.15 ⁇ 1.20, mix with the above concentrate, granulate, dry, spray the rose volatile oil evenly In the granules, mix and prepare the finished dosage form.
  • mice were randomly divided into two groups according to their body weights: blank control group (Control, C) and test drug group (the traditional Chinese medicine composition group, ZY), with 10 rats in each group.
  • blank control group Control, C
  • test drug group the traditional Chinese medicine composition group, ZY
  • the dosage of the drug is 0. lml/. 10g body weight.
  • the control group was given an equal volume of distilled water. Gavage once a day for 30 consecutive days. Each group of mice were fed a normal diet, free to eat and drink.
  • Test indicators mouse phagocytic function of peritoneal macrophages; mouse thymus coefficient and spleen index; carbon particle clearance function; ConA-induced mouse lymphocyte transformation assay and NK cell activity assay; serum hemolysin determination and antibody Generate a cell assay.
  • the measurement data is represented by ⁇ and analyzed by SPSS10.0 software.
  • mice Effects of mouse spleen lymphocyte proliferation ability and delayed type hypersensitivity in mice
  • the Chinese medicine composition group ( ⁇ ) of the present invention significantly increased the serum hemolysin level of the mouse ( ⁇ ⁇ 0.05).
  • the results are shown in Table 3.
  • Table 3 Effect on serum levels of hemolysin (; ⁇ 5)
  • the traditional Chinese medicine composition group (ZY) of the present invention significantly increased the number of hemolytic plaques (p ⁇ 0.05, /? ⁇ 0.01).
  • the traditional Chinese medicine composition group can enhance the proliferation of mouse spleen lymphocytes induced by ConA, enhance the DTH response induced by DNFB in mice, significantly increase the serum hemolysin level of mice, and increase the mice. Percentage of peritoneal macrophages phagocytosis and mouse carbon particle clearance function, and can significantly increase the number of hemolytic plaques. According to the criteria for judging the immune function in the Technical Specification for Health Food Inspection and Evaluation (2003), it is considered that the traditional Chinese medicine composition group (ZY) has an effect of enhancing immune function.
  • Experiment 2 Study on anti-allergic effect of the present invention
  • mice were randomly divided into two groups according to body weight, namely, a blank control group (Control, C), a test drug group (the present drug composition group, ZY), and 10 mice in each group.
  • the dose of the mouse of the traditional Chinese medicine composition group of the present invention was 1.65 g of crude drug/kg body weight, and the drug was formulated into a corresponding concentration before administration. Administered by intragastric administration, the administration volume is O.lml/lOg body weight.
  • the control group was given an equal volume of distilled water. Gavage once a day for 10 consecutive days. Each group of mice were fed a normal diet, free to eat and drink.
  • Rat anti-ovalbumin antiserum was prepared according to literature methods. Rat antiserum diluted 5 times with normal saline was injected into the left and right auricles of mice. After 48 hours, 1% Evans blue physiological saline solution (containing ovalbumin 1 mg/ml) was intravenously administered 10 ml/kg, and blood was released after 30 minutes. The mice were sacrificed, and the auricles on both sides were taken and digested in IN KOH solution overnight, neutralized with 0.6 NH 3 PO 4 , extracted with acetone, and the absorption value was measured at 610 nm. Evans blue exudation per ear was calculated from the standard curve. The data for each mouse is expressed as the mean of the left and right auricles. 1 h after the last administration, the experimental group was treated with ovalbumin. Line attack.
  • the rats were sacrificed by exsanguination.
  • the rats were intraperitoneally injected with 20 ml of Hanks' solution and gently massaged for 2 min.
  • the peritoneal fluid was collected.
  • the mast cells were separated by Ficoll gradient centrifugation and washed 4 times with phosphate buffer. The purity of mast cells was about 91%, and the cell concentration was adjusted. To 2 ' 1() 6/ml .
  • the traditional Chinese medicine composition group (ZY) of the present invention can significantly alleviate the passive skin allergic reaction in the mouse ear, and the results are shown in Table 1.
  • the pathophysiological mechanism of allergies is an immediate allergic reaction, that is, the level of immunoglobulin E (IgE) in the patient's serum is abnormally elevated, resulting in high sensitivity to antigens such as pollen, mold, dust mites and animal dander.
  • the traditional Chinese medicine composition group (ZY) can significantly alleviate the heterogeneous passive skin allergic reaction in mice; in the in vitro experiment, the traditional Chinese medicine composition group (ZY) of the present invention also exhibits significant release of histamine from the rat abdominal mast cells induced by compound 48/80. Inhibition, It indicates that its anti-allergic activity may be related to the stabilization of mast cell membrane and the reduction of the release of allergic mediators such as histamine.
  • Experiment 3 Study on anti-radiation effect of the invention
  • Kunming mice weighing 18 ⁇ 22g, male, clean grade, purchased from Experimental Animal Center of Jiangxi College of Traditional Chinese Medicine, license number: SCXK ( ⁇ ) 2010-001.
  • the experimental animals were kept in the environment for 3 days, and the experimental environment temperature was ( 20 ⁇ 2 ) ⁇ , normal circadian rhythm, no glare, no noise, and animals were free to eat and drink.
  • the traditional Chinese medicine composition (American ginseng, Ganoderma lucidum, fermented Cordyceps powder, rose flower, Zhimu) takes rose flower to extract volatile oil, and the distilled aqueous solution is collected separately, and spare; American ginseng and Zhimu plus 60 ⁇ 80% ethanol are extracted twice.
  • the ethanol solution is combined, filtered, and the filtrate is recovered and concentrated to a concentration of 1.10 ⁇ 1.15 at 60 ° C; the Ganoderma lucidum, fermented Cordyceps powder and rose medicinal residue and American ginseng, Zhimu drug residue are mixed, and 6 ⁇ 12 times the amount of water is boiled 2 ⁇ 3 times, the decoction and the above aqueous solution are combined, filtered, and the filtrate is concentrated to a relative density of 1.15 ⁇ 1.20 at 60 ° C, mixed with the above concentrated solution, granulated, dried, and volatile oil of rose Spray evenly on the granules and mix to prepare the finished dosage form.
  • the amount of the mouse administered was 1.65 g of crude drug per kg of body weight. Prior to administration, the drug is formulated to the corresponding concentration. It was administered by intragastric administration and the administration volume was 0.1 ml/10 g body weight. All groups of mice were given normal feed, free to eat and drink.
  • mice Thirty mice were randomly divided into normal control group, model group and traditional Chinese medicine composition (Chinese medicine group), with 10 rats in each group.
  • the normal group was given no treatment.
  • the model group was given distilled water, and the Chinese medicine composition group was intragastrically administered with the corresponding drug once a day.
  • the administration volume was O.lml/lOg body weight, and the mice in each group were continuously administered for 21 days. 3 hours after the last administration, except for the normal group, the other two groups were subjected to systemic one-time 60Co ⁇ -ray irradiation, the irradiation distance was 1. Om, and the irradiation dose was 7.5 Gy. After irradiation, the survival of each group of mice was observed and recorded. Body weight changes, the average survival time of each group of mice, 30d survival rate and the like were calculated.
  • mice Sixty mice were randomly divided into normal control group, model group and traditional Chinese medicine composition group according to their body weight. There were 10 groups in total, 10 in each group, and 3 groups were used to detect the DNA content of bone marrow cells. Except for the normal group, no treatment was given. The model group was given distilled water, and the other two groups were given the corresponding drugs by intragastric administration. The administration method and capacity were the same as before, and the administration was continued for 14 days. Except the normal control group, the other 4 groups were subjected to systemic one-time 60Co ⁇ -ray irradiation with an irradiation distance of 1. Om and a total irradiation dose of 3 Gy.
  • mice were collected 20 ⁇ l from the fundus before irradiation and 3 and 10 days after irradiation.
  • the WBC dilution was added and mixed, and poured into a blood cell counting plate.
  • White blood cell counts were performed under a microscope; spleens and thymus were weighed and the thymus and spleen indices were calculated. After irradiation
  • mice were sacrificed by cervical debridement, and the intact femur was taken.
  • the bone marrow cells were taken out by reference to the literature method, and the ultraviolet absorption value was measured at 260 nm by an ultraviolet spectrophotometer.
  • the experimental data were analyzed by one-way ANOVA with SPSS software.
  • the leukocyte levels themselves before and after irradiation were compared using the paired data t-test method for statistical analysis.
  • mice were irradiated, the appetite decreased, the body weight decreased, the contracture, and the activity decreased. However, the skin and hair showed no filth such as feces and secretions, the ear and tail were pale, and the body surface temperature was normal. The group was low; the activity and food intake of the mice in the Chinese medicine composition administration group were better than those in the model group. The survival of each group of mice was counted twice a day. The results are shown in Table 1.
  • the traditional Chinese medicine composition group can significantly improve the survival rate of mice irradiated by 7.5Gy rays for 30 days and prolong the survival time of irradiated mice, which is statistically significant compared with the model group (P ⁇ 0.01).
  • Table 2 shows that the number of peripheral blood leukocytes in each group of mice was not statistically different before irradiation; 3 days after irradiation, the number of peripheral blood leukocytes in the group of the Chinese medicine composition group was significantly higher than that in the model group (distilled with distilled water). Rats were statistically significant compared to the model group. It shows that the Chinese medicine composition group has a certain protective effect on animals exposed to low doses.
  • the traditional Chinese medicine composition group can improve the 30d survival rate of acute high-dose irradiated mice; increase the peripheral blood leukocyte count, thymus index and spleen index of low-dose irradiated mice, so that the DNA content of bone marrow cells of irradiated mice increases.
  • the Chinese medicine composition group has 60 C O Y-rays causing radiation damage to the spleen and thymus and repair or protection of the bone marrow.
  • the present invention is an agreement of the affiliated hospital of Jiangxi College of Traditional Chinese Medicine, and has been used in clinical granule formulations for many years. After retrospective analysis of 267 patients from January 2009 to January 2012, the results were as follows:
  • Case distribution 41 cases of allergic rhinitis, 28 cases of allergic asthma, 27 cases of allergic dermatitis, 21 cases of urticaria, 35 cases of hepatitis B, 13 cases of AIDS, 29 cases of breast cancer chemotherapy, 23 cases of leukopenia, male There were 29 cases of sexual dysfunction and 21 cases of chronic fatigue syndrome.
  • age distribution age 21 ⁇ 68 years old
  • treatment oral 6g, 3 times a day, 1 month for a course of treatment.
  • Efficacy evaluation There are three levels: (1) Significant effect: The clinical symptoms basically disappear or disappear completely, and the test indicators are basically normal or completely normal. (2) Effective: The clinical symptoms are alleviated and the test indicators are alleviated. (4) Invalid: The clinical symptoms are improved, and the test indicators are alleviated.
  • the raw materials were weighed according to the following ratios: 90 parts of American ginseng, 90 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 20 parts of rose, and 20 parts of Zhimu.
  • Preparation method The raw materials are weighed according to the prescription amount, the volatile oil is extracted from the rose, and the distilled aqueous solution is collected and spared; the American ginseng and the kiln are added with 60 ⁇ 80% ethanol for 2 times, the ethanol solution is combined, filtered, and the filtrate is recovered and the ethanol is recovered.
  • the raw materials were weighed according to the following ratios: 30 parts of American ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 25 parts of rose, and 16 parts of Zhimu.
  • Preparation method The raw materials are weighed according to the prescription amount, the volatile oil is extracted from the rose, and the distilled aqueous solution is collected and spared; the American ginseng, the kiwi, the lily are added with 60 ⁇ 80% ethanol twice, the ethanol solution is combined, the filtration is filtered, and the filtrate is recovered.
  • the raw materials were weighed according to the following ratios: 30 parts of American ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 15 parts of rose, and 6 parts of Zhimu.
  • Preparation method Weigh the raw materials according to the prescription amount, dry at 60 ⁇ 80 °C, pulverize into 40 ⁇ 100 mesh fine powder, and fill the capsule; or make water-filled pills, dry at 60 ⁇ 80 °C, package, and get.
  • the raw materials were weighed according to the following ratios: 30 parts of American ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 15 parts of rose, and 16 parts of Zhimu.
  • Preparation method Weigh the raw materials according to the prescription amount, extract the volatile oil from the rose flower, collect the distilled water solution, and mix the dregs with Ganoderma lucidum and fermented Cordyceps powder to add 2 ⁇ 12 times the amount of water to cook twice. With the above aqueous solution, filtered, the filtrate is concentrated to 60 ⁇ relative density 1. 15 ⁇ 1. 20, mixed with the equivalent amount of American ginseng extract, Zhimu extract, granulation, drying, spray the rose volatile oil evenly on the granules Medium, mix, and prepare the finished dosage form.
  • the raw materials were weighed according to the following ratios: 30 parts of American ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 22 parts of rose, and 14 parts of Zhimu.
  • Preparation method The extract corresponding to the crude drug amount of the Chinese medicinal material is weighed according to the prescription amount, and the finished dosage form prepared by the pharmacy conventional process using a pharmaceutically acceptable carrier or excipient.
  • the raw materials were weighed according to the following ratios: 30 parts of ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 22 parts of rose, and 15 parts of Zhimu.
  • Preparation method The raw materials are weighed according to the prescription amount, the volatile oil is extracted from the rose, and the distilled aqueous solution is collected and set aside; the ginseng and the kiln are added with 60 ⁇ 80% ethanol twice, and the ethanol solution is combined, filtered, and the filtrate is recovered and the ethanol is recovered.
  • the decoction and the above aqueous solution are filtered, and the filtrate is concentrated to 6 (TC relative density 1.15 to 1.20, mixed with the above concentrated solution, granulated, dried, and the rose volatile oil is uniformly sprayed on the granules, and mixed to prepare a finished dosage form.
  • Preparation method Weigh the raw materials according to the prescription amount, soak for 40 minutes with water, heat and decoct for 3 times, each time for 2 hours, add 10 times of water each time, combine 3 times of decoction to filter, and concentrate the filtrate to a proper amount and then let it cool. High-speed centrifugation and impurity removal, adding common ingredients for oral liquid, mixing evenly, and preparing into oral liquid.
  • the raw materials were weighed according to the following ratios: 30 parts of Codonopsis, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 15 parts of rose, and 6 parts of Zhimu.
  • Preparation method The raw materials are weighed according to the prescription amount, the volatile oil is extracted from the rose, and the distilled aqueous solution is collected and set aside; the codonopsis pilosula and the Zhimu are added with 60 ⁇ 80% ethanol twice, the ethanol solution is combined, filtered, and the filtrate is recovered and the ethanol is recovered.
  • the raw materials were weighed according to the following ratios: 30 parts of Radix Pseudostellariae, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 15 parts of rose, and 6 parts of Zhimu.
  • Preparation method Take the raw materials according to the prescription, extract the volatile oil from the rose, and collect the distilled aqueous solution, and set aside; the extract of Radix Pseudostellariae and Zhimu plus 60 ⁇ 80% ethanol is extracted twice, the ethanol solution is combined, filtered, and the filtrate is recovered and the ethanol is recovered.
  • the raw materials were weighed according to the following ratios: 30 parts of ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 15 parts of rose, 6 parts of Zhimu, and 10 parts of Ganoderma lucidum spore powder.
  • Preparation method Take the raw materials according to the prescription, extract the volatile oil from the rose, collect the distilled aqueous solution, and set aside; Ginseng and Zhimu add 60 ⁇ 80% ethanol for extraction twice, combine the ethanol solution, filter, and recover the ethanol from the filtrate and concentrate. Concentrate to a relative density of 1.10 ⁇ 1.15 to 60 °C; Ganoderma lucidum, fermented Cordyceps powder and rose medicinal residue and ginseng, Zhimu drug residue mixed, add 6 ⁇ 12 times the amount of water to cook 2 ⁇ 3 times, combine fry The solution and the above aqueous solution are filtered, and the filtrate is concentrated to a relative density of 1.15 to 1.20 at 60 ° C. Ganoderma lucidum spore powder is added, mixed with the above concentrated solution, granulated, dried, and the rose volatile oil is evenly sprayed in the granules, and mixed. Prepare the finished dosage form.
  • Preparation method Take the raw materials according to the prescription, extract the volatile oil from the rose, collect the distilled aqueous solution, and set aside; Ginseng and Zhimu add 60 ⁇ 80% ethanol for extraction twice, combine the ethanol solution, filter, and recover the ethanol from the filtrate and concentrate.
  • the carrier or excipient is in any dosage form made by conventional pharmaceutical practice.
  • the raw materials were weighed according to the following ratios: 30 parts of ginseng, 40 parts of Ganoderma lucidum, 20 parts of fermented Cordyceps powder, 15 parts of rose, 6 parts of Zhimu, 10 parts of Ganoderma lucidum spore powder, and 10 parts of Ganoderma lucidum spore oil.
  • Preparation method Take the raw materials according to the prescription, take the raw materials according to the prescription, extract the volatile oil from the rose, collect the distilled aqueous solution, and set aside; ginseng, Zhimu plus 60 ⁇ 80% ethanol extraction twice, combined with ethanol, filtered The filtrate is recovered from ethanol and concentrated to a concentration of 1.10 ⁇ 1.15 at 60 ° C; the Ganoderma lucidum, fermented Cordyceps powder and rose medicinal residue and ginseng, Zhimu drug residue are mixed, and 6 ⁇ 12 times water is added to cook 2 ⁇ 3 times, combine the decoction with the above aqueous solution, filter, concentrate the filtrate to 60 ⁇ relative density 1.15 ⁇ 1.20, add Ganoderma lucidum spore powder, mix with the above concentrate, granulate, dry, mix rose volatile oil and Ganoderma lucidum spore oil Evenly and evenly sprayed on the granules to prepare a finished dosage form.
  • the raw materials were weighed according to the following ratios: 30 parts of American ginseng, 40 parts of Ganoderma lucidum, 20 parts of Cordyceps sinensis, 25 parts of rose, and 16 parts of Zhimu.
  • Preparation method Take the raw materials according to the prescription, extract the volatile oil from the rose, and collect the distilled aqueous solution, and use it; use the American ginseng and the kiln to add 60 ⁇ 80% ethanol for 2 times, combine the ethanol solution, filter, and recover the ethanol from the filtrate and concentrate.
  • the raw materials were weighed according to the following ratios: 10 parts of American ginseng extract, 14 parts of Ganoderma lucidum extract, 12 parts of Cordyceps extract, 10 parts of rose extract, and 11 parts of Zhimu extract.
  • Preparation method The raw materials are weighed according to the prescription amount, dried at 60 ⁇ 80 ° C, and then sieved through a 40-100 mesh sieve to obtain a fine powder.
  • the raw materials were weighed according to the following ratios: 15 parts of American ginseng saponin, 18 parts of Ganoderma lucidum polysaccharide, 13 parts of Cordyceps polysaccharide, 15 parts of rose flavonoids, and 18 parts of timosaponin.
  • Preparation method The raw materials are weighed according to the prescription amount, dried at 60 ⁇ 80 ° C, and then sieved through a 40-100 mesh sieve to obtain a fine powder.
  • Preparation method The raw materials are weighed according to the prescription amount, dried at 60 ⁇ 80 ° C, and then sieved through a 40-100 mesh sieve to obtain a fine powder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)

Abstract

一种调节免疫的中药组合物及其制备方法,其中中药组合物含有西洋参、灵芝、发酵虫草菌粉、玫瑰花、知母、百合等原料,通过粉碎、水煎、醇提等方法制成各种常规药用制剂。该中药组合物具有防治过敏性疾病、乙型肝炎、艾滋病、升高白细胞、防治辐射损伤、减缓放化疗引起的毒副反应、改善男性性功能、增强人体免疫功能、缓解体力疲劳的作用。

Description

一种调节免疫的中药组合物及其制备方法 一、 技术领域
本发明涉及一种调节免疫的中药组合物及其制备方法。
二、 背景技术
免疫系统 (immune system) 是机体保护自身的防御性结构, 在疾病的发生发展 和预防中起重要作用。 现代免疫学认为, 人体的免疫功能有防御传染、 自身稳定和免 疫监视三大作用, 在正常情况下, 机体保持平衡状态, 并依靠免疫功能, 抵抗各种感 染, 清除体内有害物质, 即 "自我识别"、 "排除异己", 达到自身稳定的生理保护作 用。 但当免疫功能异常时, 自身的稳态就会被打破, 而导致多种自身免疫性疾病, 如 类风湿性关节炎、 红斑狼疮、 硬皮病、 白塞氏病、 艾滋病及其它疾病的发生, 而且与 肿瘤、 高血压、 糖尿病等疾病的发生均有密切联系。
中医把维护人体正常功能, 抗御与清除各种有害因子的作用称为 "正气", 那些有 害因子则称为 "邪气"。 "正气"相当于人体免疫功能, "邪气"又分 "外邪"与 "内邪", 即各种致病因素。 "正气内存, 邪不可干", 说明体内免疫功能正常就可以抵挡外界致病 因子, 即使侵犯人体, 也可抵御消灭。 "邪之所凑, 其气必虚", 如果免疫功能低下, 则 正常生理功能可受破坏而发病。 中医认为疾病的发生、 发展和转归取决于正邪的消长, 与机体的免疫功能密切相关, 从而提出了 "扶正祛邪"的主要治病原则。 中药多为天然 药物, 药性温和, 不良反应少, 在协调机体整体平衡、 增强机体抗病能力方面具有独特 的药效。 现代科学研宄证明人参、 黄芪、 灵芝、 枸杞、 板蓝根、 金银花等 200多种具有 扶正或祛邪功效的中药均有良好的免疫调节作用, 可调节机体免疫功能的各环节。
本发明中药组合物 (含有西洋参、 灵芝、 发酵虫草菌粉、 玫瑰花、 知母、 百合等原 料) 是在临床经验的基础上, 结合现代研究成果, 经临床和实验研宄优化组方而成, 具 有补气养阴, 益肾补肺, 理气化瘀, 清热润肺, 祛邪扶正, 调节免疫之功效。 临床研究 表明, 本发明中药组合物可增强机体免疫力, 对过敏性疾病包括过敏性鼻炎、 过敏性哮 喘、 过敏性皮炎、 荨麻疹, 病毒性疾病包括乙型肝炎、 艾滋病具有明显疗效, 并可升高 白细胞, 防治辐射损伤, 减缓化疗引起的毒副作用。
三、 发明内容
本发明的目的在于提供一种调节免疫的中药组合物及其制备方法, 具有补气养阴, 益肾补肺, 理气化瘀, 清热润肺, 祛邪扶正, 调节免疫之功效, 适用于防治过敏性疾病 包括过敏性鼻炎、 过敏性哮喘、 过敏性皮炎、 荨麻疹, 病毒性疾病包括乙型肝炎、 艾滋 病, 并可升高白细胞, 防治辐射损伤, 减缓化疗引起的毒副反应, 还可改善男性性功能。
本发明的技术方案:
一种调节免疫的中药组合物, 其特征在于以中医 "扶正祛邪"治则立法, 方中君药 西洋参性味苦、 微甘, 寒, 具有补气养阴、 清火生津之功效, 现代研究表明西洋参具有 广泛的生物学活性, 主要有效成分为西洋参多糖、 皂甙等化合物和微量元素, 可作用于 多种免疫活性细胞, 促进某些细胞因子的分泌来进一步发挥免疫调节作用。 它对免疫抑 制剂造成的免疫低下有明显的保护作用, 因而对临床肿瘤放疗患者, 慢性放射病患者及 各种原因造成免疫低下患者可以起到很有效的辅助治疗作用。西洋参可明显延长小鼠负 重游泳时间,提高小鼠的运动耐力,并有剂量反应关系; 使运动后的小鼠的肝糖原消耗量 明显减少,能够增加肝糖原贮备,维持运动时血糖水平; 减少乳酸含量, 提高小鼠的有氧 代谢能力,使酵解过程中产生的乳酸不容易在肌肉中累积,从而延缓疲劳的产生; 降低运 动时的血清尿素氮含量, 能使机体对负荷的适应性增强,并加速疲劳的消除。
臣药灵芝、 冬虫夏草助君药西洋参补气养阴, 益肾补肺, 其中灵芝性味甘, 平, 具 有补气养血、 止咳平喘、 养心安神之功效, 现代研究表明灵芝的免疫调节作用主要是灵 芝多糖在发挥药效。 灵芝多糖能显著增强机体免疫功能, 如增强小鼠迟发型过敏反应、 促进淋巴细胞增殖反应、 增强细胞毒细胞功能、 增强巨噬细胞吞噬功能、 增强 NK细胞 的细胞毒活性以及促进细胞因子的生成。 灵芝多糖还具有抗疲劳、 提高机体运动能力的 功效。对小鼠灌胃灵芝多糖后可明显延长小鼠力竭游泳时间及耐缺氧时间,提高肝糖原水 平,降低大强度定量负荷运动后血乳酸及血尿氮水平。冬虫夏草性味甘, 温, 具有益肾补 肺、 止血化痰之功效, 现代研究冬虫夏草在增强机体免疫功能方面作用明显, 此外可以 显著增加经地塞米松免疫抑制作用后的胸腺和脾脏的质量, 提高脏器指数的作用, 并具 有保护免疫性肝损伤。 虫草菌丝体及其子实体提取液可以增强机体的免疫调节功能: 促 进 T和 B淋巴细胞增殖作用, 降低同种异型抗原诱导的迟发型超敏反应及混合淋巴细胞 反应, 抗小鼠 Lewis肺癌、抗辐射损伤, 激活单核-巨噬细胞系统及提高机体的免疫功能 特别是体液免疫水平等。 虫草水提取液可以促进免疫细胞的增殖, 虫草发酵液在机体免 疫调节功能方面和野生虫草子实体及人工虫草菌丝体的功能相近。
佐使药玫瑰花、 知母理气化瘀, 滋阴润燥, 祛邪扶正, 助臣药抗炎和调节免疫, 其 中玫瑰花性味甘、 微苦, 温, 具有行气解郁、 和血散结之功效, 现代药理研究表明, 玫 瑰花的药理作用广泛, 尤其是在心血管疾病、免疫炎症的治疗与抗肿瘤、抗氧化、利胆、 解毒等方面具有作用。 知母性味苦、 甘、 寒, 具有清热泻火、 滋阴润燥之功效, 现代药 理研究表明, 知母具有抗炎、 抗氧化、 抗病毒、 抗肿瘤和免疫调节等作用, 其中活性成 分芒果苷能增加老化红细胞数量, 老化红细胞可提高 T淋巴细胞 IL-2的分泌水平, 提 高机体的免疫水平, 这与红细胞增强淋巴细胞因子分泌功能结果相似。 这种作用可能与 芒果苷的抗脂质过氧化、 稳定红细胞膜受体活性有一定的关系。
诸药合用, 共奏补气养阴, 益肾补肺, 理气化瘀, 清热润肺, 祛邪扶正之功效。 以上诸药的现代药理研究表明, 均有不同程度的抗炎及免疫调节作用, 结合中医理论辨 证用药, 中西协同互参, 相得益彰。
根据中药组方功效等同代换原则, 上述中药组合物中补气药西洋参可以换成同类补 气药人参、 党参、 太子参或黄芪中的任何一种或人参提取物、 党参提取物、 太子参提取 物或黄芪提取物中的任何一种; 补阳药发酵虫草菌粉可以换成冬虫夏草或虫草提取物。 此外, 在中药组合物中加入灵芝孢子粉和或灵芝抱子油, 可提高灵芝免疫调节作用。
一种调节免疫的中药组合物, 其特征在于包含下述原料和重量配比制备而成: 西洋 参 1〜100份, 灵芝 1〜100份, 发酵虫草菌粉 〜 60份, 玫瑰花 1〜60份, 知母 1〜60 份。
如上所述的中药组合物, 其特征在于原料的重量配比是: 西洋参 10〜90份, 灵芝 10〜90份, 发酵虫草菌粉 5〜50份, 玫瑰花 5〜50份, 知母 5〜50份。
如上所述的中药组合物,其特征在于原料的重量配比是: 西洋参 30份,灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 25份, 知母 16份。
如上所述的中药组合物, 其特征在于在其原料配比中还可加入 10〜50份的百合或 或相当于百合生药量的采用药学常规方法制备的百合提取物,以增强其抗疲劳、耐缺氧、 抗肿瘤和免疫调节作用。 百合性味甘, 微寒, 具有润肺止咳、 清心安神之功效, 现代药 理研究表明, 百合具有抗疲劳、 耐缺氧、 抗肿瘤和免疫调节等作用, 其活性成分百合多 糖具有多种生理功能: ①抗氧化、 抗疲劳功能。 百合粗多糖具有抗氧化作用,可使 D-半 乳糖引起的衰老小鼠血液中 SOD、 过氧化氢酶和谷胱甘肽酶活力升高。 ②清除自由基、 抗衰老功能。 与常见抗氧化剂 (硫脲、 抗坏血酸、 苯甲酸等)清除羟自由基能力相对照,百 合提取液的清除效果明显较佳。 ③提高免疫力和抗肿瘤作用。 百合多糖能增强免疫抑制 小鼠的非特异性和特异性免疫功能。 ④降血糖作用。 百合多糖对四氧嘧啶引起的糖尿病 模型小白鼠有明显的降血糖作用。
如上所述的中药组合物, 其特征在于西洋参可以换成人参、 党参、 太子参或黄芪中 的任何一种或人参提取物、 党参提取物、 太子参提取物或黄芪提取物中的任何一种; 发 酵虫草菌粉可以换成冬虫夏草或虫草提取物。
如上所述的中药组合物, 其特征在于在其原料配比中还可加入 10〜50份的灵芝孢 子粉和或灵芝孢子油。
如上所述的中药组合物, 其特征在于发酵虫草菌粉为生物发酵制备, 发酵虫草菌粉 所属的菌种包括蝙蝠蛾拟青霉、 蝙蝠蛾被毛孢、 中华束丝孢、 粉红胶霉、 孢霉属真菌、 麦角菌科真菌冬虫夏草头孢或中华被毛孢。
如上所述的中药组合物, 其特征在于所述原料的来源可以是中药材或者是相当于中 药材生药量的采用药学常规方法制备的提取物, 如西洋参提取物、 灵芝提取物、 玫瑰花 提取物、 知母提取物、 百合提取物。
如上所述的中药组合物, 其特征在于所述原料可以是相当于中药材生药量提取的有 效部位, 如西洋参皂甙和或西洋参多糖、 灵芝多糖和或灵芝三萜类化合物、 虫草多糖和 或虫草氨基酸、 玫瑰花黄酮和或玫瑰花油、 知母皂苷和或芒果苷。
如上所述的中药组合物, 其特征在于制备方法是采用药学上可接受的载体或赋形剂 按药剂学常规工艺制备而成。
如上所述的中药组合物, 其特征在于制备方法可通过以下 5种工艺路线获得:
( 1 ) 按上所述的中药组合物原料和重量配比分别取药材, 60〜80°C干燥、 粉碎成 40〜100目细粉, 装胶囊; 或制水泛丸, 在 60〜80°C以下干燥, 包装, 即得。
(2 )按上所述的中药组合物原料和重量配比分别取药材,加 6〜12倍量水浸泡 20〜 60分钟后, 加热煎煮 1〜3次, 每次 1〜2小时, 合并煎煮液过滤, 滤液浓縮至适量后放 冷, 高速离心除杂, 再单独或加入药学上可接受的辅料, 制备成品剂型
( 3 ) 按上所述的中药组合物原料和重量配比分别取药材, 玫瑰花提取挥发油, 蒸 馏后的水溶液另器收集, 备用; 西洋参、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用; 灵芝、发酵虫草 菌粉与玫瑰花药渣及西洋参、 知母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液 与上述水溶液, 滤过, 滤液浓缩至 60°C相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒于颗粒中, 混匀, 制备成品剂型。
(4 ) 按上所述的中药组合物原料和重量配比分别取药材, 玫瑰花提取挥发油, 蒸 馏后的水溶液另器收集, 药渣与灵芝、 发酵虫草菌粉二味药加 6〜12倍量水煎煮 2次, 合并煎液与上述水溶液, 滤过, 滤液浓缩至 60°C相对密度 1.15〜1.20, 与处方量相等的 西洋参提取物, 知母提取物混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒于颗粒中, 混 匀, 制备成品剂型。
( 5 ) 按上所述的中药组合物原料和重量配比分别取相当于中药材生药量的提取物 或有效部位, 采用药学上可接受的载体或赋形剂按药剂学常规工艺制成的成品剂型 如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是釆用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
如上所述的中药组合物, 其特征在于制备防治过敏性疾病的保健食品或药品中的应 用, 其中过敏性疾病包括过敏性鼻炎、 过敏性哮喘、 过敏性皮炎、 荨麻疹。
如上所述的中药组合物, 其特征在于制备防治病毒性疾病的保健食品或药品中的应 用, 其中病毒性疾病包括乙型肝炎、 艾滋病。
如上所述的中药组合物, 其特征在于制备具有升高白细胞作用的保健食品或药品中 的应用。
如上所述的中药组合物, 其特征在于制备具有防治辐射损伤的保健食品或药品中的 应用。
如上所述的中药组合物, 其特征在于制备减缓放化疗引起的毒副反应的保健食品或 药品中的应用。 如上所述的中药组合物, 其特征在于制备改善男性性功能的保健食品或药品中的应 用。
如上所述的中药组合物, 其特征在于制备增强人体免疫功能的保健食品或药品中的 应用。
如上所述的中药组合物, 其特征在于制备缓解体力疲劳的保健食品或药品中的应 用。
本发明的优点在于提供一种调节免疫的中药组合物及其制备方法, 具有补气养阴, 益肾补肺, 理气化瘀, 清热润肺, 祛邪扶正, 调节免疫之功效, 适用于防治过敏性疾病 包括过敏性鼻炎、 过敏性哮喘、 过敏性皮炎、 荨麻疹, 病毒性疾病包括乙型肝炎、 艾滋 病, 并可升高白细胞, 缓解疲劳, 防治辐射损伤, 减缓化疗引起的毒副反应, 还可改善 男性性功能。 本发明调节免疫与抗过敏研究 实验一 本发明免疫调节作用研究
1.材料与方法
1.1实验动物
昆明种小鼠, 体重 18〜22g, 雌性, 清洁级, 购自江西中医学院实验动物中心, 许 可证号: SCXK (赣) 2010-001
1.2实验用药
本发明中药组合物 (西洋参、 灵芝、 发酵虫草菌粉、 玫瑰花、 知母) 取玫瑰花提取 挥发油, 蒸熘后的水溶液另器收集, 备用; 西洋参、 知母加 60〜80%乙醇提取 2次, 合 并乙醇液,滤过,滤液回收乙醇并浓缩至 60Ό相对密度 1.10〜1.15的浓缩液备用;灵芝、 发酵虫草菌粉与玫瑰花药渣及西洋参、 知母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩至 60°C相对密度 1.15〜1.20, 与上述浓缩液混 匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒于颗粒中, 混匀, 制备成品剂型。
1.3 实验方法
1.3.1 动物分组: 小鼠按体重随机分为二组, 分别为空白对照组 (Control, C)、 受试药 组 (本发明中药组合物组, ZY), 每组 10只。
1.3.2 剂量设计: 本发明中药组合物组小鼠给药量为 1. 65g生药 /kg体重, 给药前, 将药 物配成相应浓度再灌胃给药, 给药体积为 0. lml/10g体重。 对照组给予等体积蒸馏水。 每日灌胃 1次, 连续 30天。 各组小鼠均饲以普通饲料, 自由进食、 饮水。
1.3.3 检验指标: 小鼠腹腔巨噬细胞吞噬功能; 小鼠胸腺系数和脾脏指数; 碳粒廓清功 能; ConA诱导的小鼠淋巴细胞转化实验和 NK细胞活性测定; 血清溶血素的测定和抗 体生成细胞检测。
1.4 统计方法:
计量数据以 ^表示, 采用 SPSS10.0软件分析。
2 结果
2.1 对小鼠胸腺系数和脾脏指数的影响
与空白对照组 (C) 比较, 本发明中药组合物组 (ZY) 对小鼠胸腺系统、 脾脏指数 无显著性差异 ( >0.05 )。 结果见表 1。 对小^胸腺系数和脾脏指数的影响 ( ±
剂量 动物数 脾脏指数 组别
(g生药 ¾) (只) < mg/g)
C ― 10 2.73±0.34 3.51±0.47
ZY 1.65 10 2.82±0.49 3.62±0.65
2.2 对小鼠脾淋巴细胞增殖能力和小鼠迟发型变态反应的影响
与空白对照组 (C) 比较, 本发明中药组合物组 (ZY) 可显著增强 ConA诱导的脾 淋巴细胞增殖和小鼠对 DNFB诱发的 DTH反应 (p<0.05或 /?<0.01), 实验结果见表 2。 表 2 对小鼠细胞免疫功能的影响( -±s)
剂量 动物数 ConA诱导脾淋巴细胞増 D FB诱导 DTH左右耳 组别
(g生药 g) (只) 殖 OD差值 重量差 (mg)
C ― 10 O.052±O.O15 9.13±0J5
ZY 1.65 10 0.089±0,017** 12.87±1.13** 注: 与空白对照组比较: * <0.05 , **^ 0.0Κ
2.3 对小鼠血清溶血素水平的影响
与空白对照组 (C ) 比较, 本发明中药组合物组 (ΖΥ) 有显著提高小鼠血清溶血素 水平的作用 (ρ<0.05)。 结果见表 3。 表 3 对小^血清溶血素水平的影响(;·=5)
剂量
组别 动物数(只) 血清洚血素 (抗体积数)
C 10 52.15±6.83 ΖΥ 1.65 10 76,27=8.15** 注: 与 ΐ白对照组比较: * p <0.OS , " p <0.0 2.4 对小鼠腹腔巨噬细胞吞噬功能的影响- 与空白对照组 (C) 比较, 本发明中药组合物组 (ZY) 有显著提高小鼠腹腔巨噬细 胞吞噬百分率的作用 (p<0.01)。 结果见表 4。
表 4 对腹腔巨噬细胞吞噬功能的影响 ( x±5)
剂量
组别 动物数(只) 吞 OS百分率 (%)
(g生药, ¾g)
C ― 10 27.37±1.52
ZY 1.65 10 35.6 2.43** 注:与: £白对照组比较: *^<0.05, ** <0.01。
2.5 对小鼠碳粒廓清功能的影响:
与空白对照组 (C) 比较, 本发明中药组合物组(ZY) 有显著提高吞噬指数的作用 (p<0.05或/ ?<0.01)。 结果见表 5。 表 5 对小鼠碳粒廓清功能的影响(-ϊ±5)
剂量
钽别 动物数〈只) 吞噬指数
(g生药 . )
C ― 10 5.12±0.23
ΣΥ 1.65 10 7.42±0.31**
注: 与空白对照组比较: *p<Q.05, **p -0.01。
2.6 对小鼠抗体生成细胞功能的影响
与空白对照组 (C) 比较, 本发明中药组合物组 (ZY) 有显著提高溶血空斑数的作 用 (p<0.05, /?<0.01)c 结果见表 6。 表 6 对小^抗体生成细胞功能的影响( .;ZJ)
剂量 洚血 斑数
组别 动物数(只)
(g生药: ·!¾) ( 10胸细胞)
C ― 10
ZY 1.65 10 289.5=21.7** 注:与: ί:白对照组比较: *^<0.05, **^<0.01ο
2.7 对小鼠 ΝΚ细胞活性的影响
与空白对照组 (C) 比较, 本发明中药组合物组 (ΖΥ) 对小鼠 ΝΚ细胞活性无显著 性差异 (/?>0.05), 结果见表 7。 表 7 咅组对小^ Κ细胞活性的影响( ±5)
剂量
组别 动物数(只) 细胞活性( )
(g生药 g)
C ― 10
ZY 1.65 10 10.03±2.75 注:与空白对照组比较: *ρ<0.05, ** <0.01ο 3. 结论
动物实验研究表明: 本发明中药组合物组(ZY)可提高小鼠 ConA诱导的脾淋巴细 胞增殖能力, 增强小鼠对 DNFB诱发的 DTH反应, 有显著提高小鼠血清溶血素水平、 提高小鼠腹腔巨噬细胞吞噬百分率和小鼠碳粒廓清功能的作用, 并可显著增加溶血空斑 数。 根据 《保健食品检验与评价技术规范 (2003 )》 中增强免疫功能的结果判定标准, 认为本发明中药组合物组 (ZY) 具有增强免疫功能的作用。 实验二 本发明对抗过敏作用研究
1 材料与方法
1.1 实验动物
动物雄性 ICR小鼠, 体重 18〜22 g, 雄性 SD大鼠, 体重 180〜200g, 购自江西中医学 院实验动物中心,许可证号: SCXK (赣) 2010—001。
1.2 实验试剂
卵白蛋白 (ovalbumin) 和 compound 48/80, Sigma公司产品; 灭活百日咳杆菌
( Bordetella pertussis)、 Ficoll和邻苯甲醛( o-phthala ldehyde, OPT), Wako公司产品; 色 甘酸二钠( disodium cromogly cate, DSCG), Biomol公司产品。
1.3实验用药
同 "实验一" 。
1.4动物分组与给药
小鼠按体重随机分为二组, 分别为空白对照组(Control, C)、 受试药组(本发明中 药组合物组, ZY), 每组 10只。 本发明中药组合物组小鼠给药量为 1.65g生药/ kg体重, 给药前, 将药物配成相应浓度。 灌胃给药, 给药体积为 O.lml/lOg体重。 对照组给予等 体积蒸馏水。 每日灌胃 1次, 连续 10天。 各组小鼠均饲以普通饲料, 自由进食、 饮水。
1.5小鼠异种被动皮肤过敏反应
按文献方法制备大鼠抗卵白蛋白抗血清。 在小鼠左、 右耳廓内注入经生理盐水 5倍 稀释的大鼠抗血清 10μ1, 48h后静脉注射 1% Evans蓝生理盐水溶液( 内含卵白蛋白 lmg/ml ) 10ml/kg, 30min后放血处死小鼠, 取两侧耳廓, 分别置于 IN KOH溶液中消化 过夜,以 0.6 NH3PO4中和,经丙酮抽提, 610nm处测定吸收值,由标准曲线计算每耳 Evans 蓝渗出量, 各鼠的数据以左、 右耳廓的均值表示。 末次给药后 lh, 实验组用卵白蛋白进 行攻击。
1.6 Compound 48 /80诱导大鼠腹腔肥大细胞释放组胺
将大鼠放血处死, 腹腔注射 Hanks'液 20ml 轻轻按摩 2min, 收集腹腔液, 以 Ficoll梯 度离心法分离肥大细胞, 经磷酸缓冲液洗涤 4次, 肥大细胞的纯度约为 91%, 调整细胞 浓度至 2 ' 1()6/ml。 取肥大细胞悬液 0.9ml 在 37°C预温孵 10min, 加入受试样品 50 μΐ温孵 5min后, 试管中加入 compound 48/80 50μ1 (终浓度为 0^g'ml4 ), 自发释放管中加入磷酸 缓冲液 50μ1温孵 lOmin后, 将试管转移至冰浴冷却, 终止反应。 3 000r/min离心 10min, 以荧光法测定上清液 (释放量)及沉淀中 (残留量)的组胺含量。 组胺释放率按下式计算: 释放率(%)= (释放量-自发释放量) /(释放量 +残留量 )χ 100%。
1.7 统计学处理
实验结果以; ^表示, 组间差异以 t检验作统计学处理。
2 结果
2.1 对小鼠异种被动皮肤过敏反应的影响
由表 1可见, 本发明中药组合物组(ZY)可显著减轻小鼠耳异种被动皮肤过敏反应, 结果见表 1。
表 1 对小鼠耳异种被动皮肤过敏反应的影响( x±s)
剂量 Evans蓝 抑制率
组别 n
(g生药 ¾) ')参出量 m':''ug (%)
C 10 4.93±1.21
ZY 10 1.65 1.52±1.29* 69.2 注:与 S白对照组比较: * 0-05, ** p <0.01。
2.2对 Compound 48/80诱导大鼠腹腔肥大细胞释放组胺的影响
与空白对照组(C) 比较, 本发明中药组合物组(ZY)对 Compound 48 /80诱导的大 鼠腹腔肥大细胞释放组胺有显著的抑制作用。 结果见表 2。
表 2 对 CompouncHS Έ0诱导大 ^腹腔肥大细胞释放组胺的影响 (;±5, n=3)
Figure imgf000010_0001
注:与空白对照组比较: *^ <o-05, **p <om .
综上所述,过敏的病理生理机制为速发型过敏反应,即患者血清中免疫球蛋白 E(IgE) 水平异常升高, 以致对花粉、 霉菌、 尘螨及动物皮屑等抗原出现高敏感性。 本发明中药 组合物组 (ZY) 能明显减轻小鼠异种被动皮肤过敏反应; 体外实验中, 本发明中药组 合物组(ZY)对 compound 48/80诱导大鼠腹腔肥大细胞释放组胺亦呈现显著的抑制作用, 表明其抗过敏活性可能与稳定肥大细胞膜、 减少组胺等过敏介质的释放有关。 实验三 本发明抗辐射作用研究
1 材料
1.1实验动物
昆明种小鼠, 体重 18〜22g, 雄性, 清洁级, 购自江西中医学院实验动物中心, 许 可证号: SCXK (赣) 2010— 001。 实验动物饲养适应环境 3d后进行实验,词养环境温度 为 (22) Ό,正常昼夜节律,无强光、 噪音剌激,动物可自由地进食和饮水。
1.2实验用药
本发明中药组合物 (西洋参、 灵芝、 发酵虫草菌粉、 玫瑰花、 知母)取玫瑰花提取 挥发油, 蒸馏后的水溶液另器收集, 备用; 西洋参、 知母加 60〜80%乙醇提取 2次, 合 并乙醇液,滤过,滤液回收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用;灵芝、 发酵虫草菌粉与玫瑰花药渣及西洋参、 知母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓縮至 60°C相对密度 1.15〜1.20, 与上述浓缩液混 匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒于颗粒中, 混匀, 制备成品剂型。 小鼠给药 量为 1.65g生药 /kg体重。给药前,将药物配成相应浓度。灌胃给药,给药体积为 0.1ml/10g 体重。 各组小鼠均伺以普通饲料, 自由进食、 饮水。
1.3 实验仪器
Olympus 显微镜(日本奥林巴斯公司),全自动生化分析仪(日本岛津),离心机 (北京 产),紫外光分光光度计(UV-2401PC,日本产)。
2 方法
2. 1 30d存活率、 存活天数测定
取小鼠 30只,随机分成正常对照组、 模型组、 中药组合物 (中药组) 3组,每组 10 只。 正常组不予任何处理,模型组给予蒸馏水, 中药组合物组灌胃给予相应药物,每天 1 次,给药体积均为 O.lml/lOg体重,各组小鼠连续给药 21d。 末次给药后 3h,除正常组外, 其余 2组均进行全身一次性 60Co γ射线照射,照射距离为 1. Om,照射剂量为 7. 5Gy,照射 后观察记录各组小鼠的生存状况、体重变化,计算各组小鼠的平均生存时间、 30d存活率 等。
2. 2 外周血白细胞计数、 骨髓细胞 DNA含量测定、 胸腺、 脾脏指数测定
取 60只小鼠,按照体重随机分成正常对照组、 模型组、 中药组合物组各 2组,共 10 组,每组 10只,其中 3组用于检测骨髓细胞 DNA含量。除正常组不予任何处理,模型组给 予蒸馏水,其他 2组灌胃给予相应药物,给药方法和容量同前,连续给药 14d。除正常对照 组外,其余 4组均进行全身一次性 60Co γ射线照射,照射距离为 1. Om,总照射剂量为 3Gy。 小鼠于照射前和照射后 3、 10d,眼底采血 20μ1 ,加入 WBC稀释液混匀,倒入血球计数板中, 显微镜下进行白细胞计数; 同时取出脾脏和胸腺称量,计算胸腺、 脾脏指数。 照射后第
3d,颈椎脱白处死小鼠,取完整股骨,除净软组织,参照文献方法取出骨髓细胞,提取,用 紫外分光光度计在 260nm处测定紫外吸收值。
2.3 统计方法
实验数据以 SPSS软件进行单因素方差分析。 照射前后白细胞水平自身比较应用配 对资料 t检验方法进行统计分析。
3 结果
3.1 小鼠一般状况和 30d存活率小鼠受到照射后食欲下降,体重减轻,蜷缩,活动减少, 但皮肤毛发未见粪便和分泌物等污秽的表现,耳廓及尾部苍白,体表温度较正常组低; 中 药组合物给药组小鼠活动和进食量好于模型组。 每日 2次统计各组小鼠存活数。 结果见 表 1。
对受照 .5Gy小鼠 30d存活率和存活时间的影响 G±5)
剂重
组别 动物数 存活数 存活率 (《) 存活时间(d)
(g生药 kg)
正常组 - 10 10 100 30.0 ± 0.0** 模型组 - 10 0 0 7.23 ±5.31 中药组 1.65 10 3 30 15.65 ±6.43** 注:与模型组比较, *P<0.05, **P<0.01。
表 1可见, 中药组合物组可以明显提高受 7.5Gy射线照射小鼠 30d存活率,延长受 照射小鼠的生存时间,与模型组比较有统计学意义 (P<0.01)。
3.2 对小鼠外周血白细胞计数、 骨髓细胞 DNA含量测定、 胸腺、 脾脏指数的影响, 结 果见表 2、 表 3。
抗辐射复方中药对小鼠照射 3Gy前后外周血白细胞计数的影响 G¾ n=10)
剂量 白细胞计数(X 10' - L-1)
组别
(g生药 kg) 觸前 照射后 3d 照射后 10d
正常组 - 8.97 ±2.31 7.82 ±2.35* 7.79 ±3.21* 模型组 - 9.08 ±2.86 2.15±2.69 4.42 ±2.53 中药组 1.65 9.10±2.72 5.27 ±2.87* 7·13±2.47* 注:与模型组比较, *Ρ<0.05ο
表 2可见,照射前,各组小鼠的外周血白细胞数无统计学差异;照射后 3d,中药组合 物组给药组小鼠外周血白细胞数明显高于模型组 (给予蒸镏水)小鼠,与模型组比较有统 计学意义。 说明中药组合物组对受到低剂量辐射动物有一定的保护作用。
对照射 3Gy后小鼠胸腺、脾脏指数和骨髓细胞 DNA含量的影响( ΐ± )
胸腺指数 脾脏指数 DNA含量
组别 动物数
(mg lOg"1) g iOg"1) (0D)
正常组 10 21.51 ±4.72** 53.97±11.13** 0.23 ±0.05* 模型组 10 10.83±5.37 32.79±10.35 0.14 ±0.07 中药组 10 16.39 ±5.12* 46.16 ±10.32* 0.18±0.06* 注:与模型组比较, *P<0.05, **P<0.01 - 表 3可以看出, 中药组合物组可以提高照射小鼠的胸腺指数和脾脏指数,并能提高 受照射小鼠骨髓细胞 DNA含量,说明中药组合物组对 60Co γ射线造成脾脏和胸腺放射损 伤和骨髓有修复或保护作用。
综上所述, 中药组合物组可提高急性大剂量受照射小鼠的 30d存活率;提高低剂量 照射小鼠外周血白细胞数、胸腺指数和脾脏指数,使受照射小鼠骨髓细胞 DNA含量增加, 说明中药组合物组对 60CO Y射线造成脾脏和胸腺放射损伤和骨髓有修复或保护作用。 实验四 本发明临床研究 本发明作为江西中医学院附属医院协定方, 在临床以颗粒剂配方使用多年。 通过对 2009年 1月至 2012年 1月 267例患者使用后回顾性分析, 结果如下:
1、 病例分布: 过敏性鼻炎 41例、 过敏性哮喘 28例、 过敏性皮炎 27例、 荨麻疹 21 例, 乙型肝炎 35例, 艾滋病 13例, 乳腺癌化疗 29例, 白细胞降低 23例, 男性性功能 减退 29例、 慢性疲劳综合症 21例。
2、 年龄分布: 年龄 21〜68岁
3、 性别分布: 男 143例, 女 124例
4、 病程分布: 3月〜 20年
5、 治疗方法: 口服 6g, 一日 3次, 1个月为 1疗程。
6、 疗效评定: 分三级: (1 ) 显效: 临床症状基本消失或完全消失, 化验指标基本 正常或完全正常。 (2 ) 有效: 临床症状减轻, 化验指标减轻。 (4) 无效: 临床症状无 明改善, 化验指标减轻。
本发明临床治疗 267例患者疗效情况
病例数 显效 有效 无效 总有效率% 过敏性鼻炎 41 21 15 5 87. 80 过敏性哮喘 28 13 11 4 85. 71 过敏性皮炎 27 11 9 7 74. 07
21 11 5 5 76. 19 乙型肝炎 35 15 11 9 74. 29 艾滋病 13 5 4 4 69. 23 白细胞降低 23 10 8 5 78. 26 乳腺癌化疗 29 12 10 7 75. 86 男性性功能减退 29 10 9 10 65. 52 慢性疲劳综合症 21 10 5 6 71. 43 总例数 267 118 87 62 76. 78 四、 具体实施方式 … ,、
说 明 书 下面以具体实施例对本发明作详细说明:
实施例 1
按照下列配比称取原料: 西洋参 90份, 灵芝 90份, 发酵虫草菌粉 20份, 玫瑰花 20份, 知母 20份。
制备方法: 按处方量称取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备 用; 西洋参、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩 至 60°C相对密度 1.10〜1.15的浓缩液备用;灵芝、发酵虫草菌粉与玫瑰花药渣及西洋参、 知母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓 缩至 60°C相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油均匀 喷洒于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 2
按照下列配比称取原料: 西洋参 10份, 灵芝 10份, 发酵虫草菌粉 5份, 玫瑰花 5 份, 知母 5份。
制备方法: 同实施例 1
实施例 3
按照下列配比称取原料: 西洋参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 25份, 知母 16份。
制备方法: 同实施例 1
实施例 4
按照下列配比称取原料: 西洋参 10份, 灵芝 10份, 发酵虫草菌粉 5份, 玫瑰花 5 份, 知母 5份, 百合 5份。
制备方法: 按处方量称取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备 用; 西洋参、 知母、 百合加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇 并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用;灵芝、发酵虫草菌粉与玫瑰花药渣及 西洋参、 知母、 百合药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩至 60°C相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰 花挥发油均匀喷洒于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 5
按照下列配比称取原料: 西洋参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15份, 知母 6份。
制备方法: 按处方量称取原料, 60〜80°C干燥、 粉碎成 40〜100目细粉, 装胶囊; 或制水泛丸, 在 60〜80°C以下干燥, 包装, 即得。
实施例 6
按照下列配比称取原料: 西洋参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15份, 知母 16份。
制备方法: 按处方量称取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 药 渣与灵芝、 发酵虫草菌粉二味药加 6〜12倍量水煎煮 2次, 合并煎液与上述水溶液, 滤 过, 滤液浓缩至 60Ό相对密度 1. 15〜1. 20, 与处方量相等的西洋参提取物、 知母提取 物混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒于颗粒中, 混匀, 制备成品剂型。
实施例 7
按照下列配比称取原料: 西洋参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 22份, 知母 14份。
制备方法: 按处方量称取相当于中药材生药量的提取物, 采用药学上可接受的载体 或赋形剂按药剂学常规工艺制成的成品剂型。
实施例 8
按照下列配比称取原料: 人参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 22 份, 知母 15份。
制备方法: 按处方量称取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备 用; 人参、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用; 灵芝、 发酵虫草菌粉与玫瑰花药渣及人参、 知 母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩 至 6(TC相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷 洒于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 9
按照下列配比称取原料: 西洋参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 25份, 知母 16份。
制备方法: 按处方量称取原料, 加水浸泡 40分钟后, 加热煎煮 3次, 每次 2小时, 每次加水 10倍量, 合并 3次煎煮液过滤, 滤液浓缩至适量后放冷, 高速离心除杂, 加 入口服液常用辅料, 混合均匀, 制备成口服液。
实施例 10
按照下列配比称取原料: 党参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15 份, 知母 6份。
制备方法: 按处方量称取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备 用; 党参、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用; 灵芝、 发酵虫草菌粉与玫瑰花药渣及党参、 知 母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩 至 60Ό相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷 洒于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 11
按照下列配比称取原料: 太子参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15份, 知母 6份。
制备方法: 按处方量取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备用; 太子参、 知母加 60〜80%乙醇提取 2 次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用; 灵芝、 发酵虫草菌粉与玫瑰花药渣及太子参、 知母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓 缩至 60Ό相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油均匀 喷洒于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 12
按照下列配比称取原料: 黄芪 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15 份, 知母 16份。 制备方法: 按处方量称取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备 用; 黄芪、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用; 灵芝、 发酵虫草菌粉与玫瑰花药渣及黄芪、 知 母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩 至 60°C相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷 洒于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 13
按照下列配比称取原料: 人参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15 份, 知母 6份, 灵芝孢子粉 10份。
制备方法: 按处方量取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备用; 人参、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C 相对密度 1.10〜1.15的浓缩液备用; 灵芝、 发酵虫草菌粉与玫瑰花药渣及人参、 知母药 渣混合,加 6〜12倍量水煎煮 2〜3次,合并煎液与上述水溶液,滤过,滤液浓缩至 60°C 相对密度 1.15〜1.20, 加入灵芝孢子粉, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥 发油均匀喷洒于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 14
按照下列配比称取原料: 人参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15 份, 知母 10份, 灵芝孢子油 10〜50份。
制备方法: 按处方量取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集, 备用; 人参、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C 相对密度 1.10〜1.15的浓缩液备用; 灵芝、 发酵虫草菌粉与玫瑰花药渣及人参、 知母药 渣混合,加 6〜12倍量水煎煮 2〜3次,合并煎液与上述水溶液,滤过,滤液浓縮至 60°C 相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油和灵芝孢子油 混匀, 均匀喷洒于颗粒中, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 15
按照下列配比称取原料: 人参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 15 份, 知母 6份, 灵芝孢子粉 10份, 灵芝孢子油 10份。
制备方法: 按处方量取原料, 按处方量取原料, 玫瑰花提取挥发油, 蒸馏后的水溶 液另器收集, 备用; 人参、 知母加 60〜80%乙醇提取 2次, 合并乙醇液, 滤过, 滤液回 收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用;灵芝、发酵虫草菌粉与玫瑰花 药渣及人参、 知母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩至 60Ό相对密度 1.15〜1.20, 加入灵芝孢子粉, 与上述浓缩液混匀, 制 粒, 干燥, 将玫瑰花挥发油和灵芝孢子油混匀, 均匀喷洒于颗粒中, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 16
按照下列配比称取原料: 西洋参 30份, 灵芝 40份, 冬虫夏草 20份, 玫瑰花 25份, 知母 16份。
制备方法: 按处方量取原料, 玫瑰花提取挥发油, 蒸馏后的水溶液另器收集,备用; 西洋参、 知母加 60〜80%乙醇提取 2 次, 合并乙醇液, 滤过, 滤液回收乙醇并浓缩至 60°C相对密度 1.10〜1.15的浓缩液备用; 灵芝、 冬虫夏草与玫瑰花药渣及西洋参、 知母 药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩至 6(TC相对密度 1.15〜1.20, 与上述浓缩液混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒 于颗粒中, 混匀, 制备成品剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以是采用药学上可接受 的载体或赋形剂按药剂学常规工艺制成的任何剂型。
如上所述的中药组合物的制备方法, 其特征在于成品剂型可以为颗粒剂、 片剂、 胶 囊剂、 煎膏剂、 滴丸剂、 丸剂、 散剂、 锭剂、 流浸膏剂、 浸膏剂、 注射剂、 糖浆剂或口 服液。
实施例 17
按照下列配比称取原料: 西洋参提取物 10份, 灵芝提取物 14份, 虫草提取物 12 份, 玫瑰花提取物 10份, 知母提取物 11份。 制备方法: 按处方量称取原料, 60〜80°C干燥后过 40〜100目筛, 将细粉装胶囊, 即得。
实施例 18
按照下列配比称取原料: 西洋参皂甙 15份, 灵芝多糖 18份, 虫草多糖 13份, 玫 瑰花黄酮 15份, 知母皂苷 18份。
制备方法: 按处方量称取原料, 60〜80°C干燥后过 40〜100目筛, 将细粉装胶囊, 即得。
实施例 19
按照下列配比称取原料: 西洋参皂甙 15份, 西洋参多糖 10份, 灵芝三萜类化合物 28份, 虫草多糖 13份, 虫草氨基酸 10份, 玫瑰花黄酮 17份, 知母皂苷 11份, 芒果苷 8份。
制备方法: 按处方量称取原料, 60〜80°C干燥后过 40〜100目筛, 将细粉装胶囊, 即得。

Claims

WO 2014/040396 , π _p. . N PCT/CN2013/001113 权 利 要 求 书
1、 一种调节免疫的中药组合物, 其特征在于包含下述原料和重量配比: 西洋参 1〜 100份, 灵芝 1〜100份, 发酵虫草菌粉 1〜60份, 玫瑰花 1〜60份, 知母 1〜60份。
2、 如权利要求 1所述的中药组合物, 其特征在于原料的重量配比是: 西洋参 10〜 90份, 灵芝 10〜90份, 发酵虫草菌粉 5〜50份, 玫瑰花 5〜50份, 知母 5〜50份。
3、 如权利要求 1或 2所述的中药组合物, 其特征在于原料的重量配比是: 西洋参 30份, 灵芝 40份, 发酵虫草菌粉 20份, 玫瑰花 25份, 知母 16份。
4、如权利要求 1〜3所述的中药组合物,其特征在于在其原料配比中还可加入 10〜 50份的百合或者是相当于百合生药量的采用药学常规方法制备的提取物。
5、如权利要求 1〜3所述的中药组合物,其特征在于在其原料配比中还可加入 10〜 50份的灵芝孢子粉和或灵芝孢子油。
6、 如权利要求 1〜3所述的中药组合物, 其特征在于西洋参可以换成人参、 党参、 太子参或黄芪中的任何一种或人参提取物、 党参提取物、 太子参提取物或黄芪提取物中 的任何一种; 发酵虫草菌粉可以换成冬虫夏草或虫草提取物。
7、如权利要求 1〜3所述的中药组合物,其特征在于发酵虫草菌粉为生物发酵制备, 发酵虫草菌粉所属的菌种包括蝙蝠蛾拟青霉、 蝙蝠蛾被毛孢、 中华束丝孢、 粉红胶霉、 孢霉属真菌、 麦角菌科真菌冬虫夏草头孢或中华被毛孢。
8、 如权利要求 1〜3所述的中药组合物, 其特征在于所述原料的来源可以是中药材 或者是相当于中药材生药量的采用药学常规方法制备的提取物, 如西洋参提取物、 灵芝 提取物、 玫瑰花提取物、 知母提取物。
9、 如权利要求 1〜3所述的中药组合物, 其特征在于所述原料可以是相当于中药材 生药量提取的有效部位, 如西洋参皂甙和或西洋参多糖、 灵芝多糖和或灵芝三萜类化合 物、 虫草多糖和或虫草氨基酸、 玫瑰花黄酮和或玫瑰花油、 知母皂苷和或芒果苷。
10、 如权利要求 1〜3所述的中药组合物, 其特征在于制备方法是采用药学上可接 受的载体或赋形剂按药剂学常规工艺制备而成。
11、 如权利要求 10所述的中药组合物, 其特征在于制备方法可通过以下 5种工艺 路线获得:
( 1 )按权利要求 1〜3所述的中药组合物原料和重量配比分别取药材, 60〜80°C干 燥、粉碎成 40〜100目细粉, 装胶囊; 或制水泛丸, 在 60〜80°C以下干燥, 包装, 即得;
( 2 )按权利要求 1〜3所述的中药组合物原料和重量配比分别取药材, 加 6〜12倍 量水浸泡 20〜60分钟后, 加热煎煮 1〜3次, 每次 1〜2小时, 合并煎煮液过滤, 滤液 浓缩至适量后放冷,高速离心除杂,再单独或加入药学上可接受的辅料,制备成品剂型;
( 3 )按权利要求 1〜3所述的中药组合物原料和重量配比分别取药材, 玫瑰花提取 挥发油, 蒸馏后的水溶液另器收集, 备用; 西洋参、 知母加 60〜80%乙醇提取 2次, 合 并乙醇液,滤过,滤液回收乙醇并浓縮至 60°C相对密度 1.10〜1.15的浓缩液备用;灵芝、 WO 2014/040396 , π -. . , PCT/CN2013/001113
权 利 要 求 书 发酵虫草菌粉与玫瑰花药渣及西洋参、 知母药渣混合, 加 6〜12倍量水煎煮 2〜3次, 合并煎液与上述水溶液, 滤过, 滤液浓缩至 60°C相对密度 1.15-1.20, 与上述浓縮液混 匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒于颗粒中, 混匀, 制备成品剂型;
(4)按权利要求 1〜3所述的中药组合物原料和重量配比分别取药材, 玫瑰花提取 挥发油, 蒸馏后的水溶液另器收集, 药渣与灵芝、 发酵虫草菌粉二味药加 6〜12倍量水 煎煮 2次, 合并煎液与上述水溶液, 滤过, 滤液浓缩至 60°C相对密度 1.15〜1.20, 与处 方量相等的西洋参提取物, 知母提取物混匀, 制粒, 干燥, 将玫瑰花挥发油均匀喷洒于 颗粒中, 混匀, 制备成品剂型;
( 5 )按权利要求 1〜3所述的中药组合物原料和重量配比分别取相当于中药材生药 量的提取物或有效部位, 采用药学上可接受的载体或赋形剂按药剂学常规工艺制成的成 品剂型。
12、 如权利要求 10或 11所述的中药组合物的制备方法, 其特征在于成品剂型可以 是采用药学上可接受的载体或赋形剂按药剂学常规工艺制成的颗粒剂、 片剂、 胶囊剂、 浸膏剂、 丸剂、 散剂、 锭剂或口服液。
13、 如权利要求 1〜3所述的中药组合物, 其特征在于制备防治过敏性疾病的保健 食品或药品中的应用, 其中过敏性疾病包括过敏性鼻炎、 过敏性哮喘、 过敏性皮炎、 荨 麻疹。
14、 如权利要求 1〜3所述的中药组合物, 其特征在于制备防治病毒性疾病的保健 食品或药品中的应用, 其中病毒性疾病包括乙型肝炎、 艾滋病。
15、 如权利要求 1〜3所述的中药组合物, 其特征在于制备具有升高白细胞作用的 保健食品或药品中的应用。
16、 如权利要求 1〜3所述的中药组合物, 其特征在于制备具有防治辐射损伤的保 健食品或药品中的应用。
17、 如权利要求 1〜3所述的中药组合物, 其特征在于制备减缓放化疗引起的毒副 反应的保健食品或药品中的应用。
18、 如权利要求 1〜3所述的中药组合物, 其特征在于制备改善男性性功能的保健 食品或药品中的应用。
19、 如权利要求 1〜3所述的中药组合物, 其特征在于制备增强人体免疫功能的保 健食品或药品中的应用。
20、 如权利要求 1〜3所述的中药组合物, 其特征在于制备缓解体力疲劳的保健食 品或药品中的应用。
PCT/CN2013/001113 2012-09-13 2013-09-22 一种调节免疫的中药组合物及其制备方法 WO2014040396A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2015531424A JP6305407B2 (ja) 2012-09-13 2013-09-22 免疫を調節する漢方薬組成物及びその製造方法
IN2833DEN2015 IN2015DN02833A (zh) 2012-09-13 2013-09-22
RU2015113319A RU2630056C2 (ru) 2012-09-13 2013-09-22 Комбинация традиционной китайской медицины для регуляции иммунной функции и способ ее получения
EP13837349.3A EP2949334B1 (en) 2012-09-13 2013-09-22 Traditional chinese medicine combination for regulating immune function and preparation method therefor
US14/428,313 US9775868B2 (en) 2012-09-13 2013-09-22 Traditional Chinese medicine combination for regulating immune function and preparation method therefor
EP19175214.6A EP3560507B1 (en) 2012-09-13 2013-09-22 Traditional chinese medicine combination for regulating immune function and preparation method therefor
KR1020157008510A KR101908381B1 (ko) 2012-09-13 2013-09-22 면역 기능을 조절하는 한약조성물 및 이의 제조방법
ZA2015/02271A ZA201502271B (en) 2012-09-13 2015-04-07 Traditional chinese medicine combination for regulating immune function and preparation method therefor
US15/698,572 US10537600B2 (en) 2012-09-13 2017-09-07 Traditional Chinese medicine combination for regulating immune function and preparation method therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210336446.2A CN103656113A (zh) 2012-09-13 2012-09-13 一种调节免疫的中药组合物及其制备方法
CN201210336446.2 2012-09-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/428,313 A-371-Of-International US9775868B2 (en) 2012-09-13 2013-09-22 Traditional Chinese medicine combination for regulating immune function and preparation method therefor
US15/698,572 Division US10537600B2 (en) 2012-09-13 2017-09-07 Traditional Chinese medicine combination for regulating immune function and preparation method therefor

Publications (1)

Publication Number Publication Date
WO2014040396A1 true WO2014040396A1 (zh) 2014-03-20

Family

ID=50277562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/001113 WO2014040396A1 (zh) 2012-09-13 2013-09-22 一种调节免疫的中药组合物及其制备方法

Country Status (10)

Country Link
US (2) US9775868B2 (zh)
EP (2) EP3560507B1 (zh)
JP (1) JP6305407B2 (zh)
KR (1) KR101908381B1 (zh)
CN (5) CN109512925A (zh)
IN (1) IN2015DN02833A (zh)
MY (1) MY179990A (zh)
RU (1) RU2630056C2 (zh)
WO (1) WO2014040396A1 (zh)
ZA (1) ZA201502271B (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015199673A (ja) * 2014-04-04 2015-11-12 日本メナード化粧品株式会社 抗疲労剤
CN108041611A (zh) * 2017-12-25 2018-05-18 大连深蓝肽科技研发有限公司 一种提高男性性能力的保健食品及其制备方法
CN111617120A (zh) * 2020-06-03 2020-09-04 广州鹰远生物科技有限公司 一种人参虫草发酵提取物的制备方法
CN111955570A (zh) * 2020-09-17 2020-11-20 傅松涛 一种增强免疫力预防肿瘤的参白灵芝茶及其生产工艺
CN113455651A (zh) * 2021-07-09 2021-10-01 杨水祥 一种含有干细胞提取液的代谢和免疫增强及改善亚健康制剂
CN114698840A (zh) * 2022-04-06 2022-07-05 颖河(焦作)中药生物工程有限责任公司 一种用于增免的天然植物提取物及其生产工艺

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103446201B (zh) * 2012-05-29 2017-11-24 江中药业股份有限公司 一种防治过敏性疾病的组合物及其制备方法
CN104138539A (zh) * 2014-07-08 2014-11-12 马鞍山市安康菌业有限公司 一种黑色素盘菌生产黑色素复配的灵芝胶囊及其制备方法
CN104491066A (zh) * 2014-12-07 2015-04-08 苏州普罗达生物科技有限公司 一种增强免疫力的花类组合物
CN104523523B (zh) * 2014-12-23 2017-06-06 桂林电子科技大学 一种具有抗电离辐射作用的复方柿单宁芦荟胶
CN107837290A (zh) * 2017-05-06 2018-03-27 长春中医药大学 一种中药制剂添加剂
CN107169078A (zh) * 2017-05-10 2017-09-15 京东方科技集团股份有限公司 中医药知识图谱及其建立方法以及计算机系统
CN107441368A (zh) * 2017-07-13 2017-12-08 广州市高纤宝健康食品有限公司 一种具有提高免疫力作用的药食同源组合物及其制备方法
CN109381505B (zh) * 2017-08-04 2022-09-16 中国辐射防护研究院 一种中药提取物及其组合物和用于抗疲劳的用途
CN108815301A (zh) * 2018-07-02 2018-11-16 西安巨子生物基因技术股份有限公司 具有促白细胞生成功效的组合物及其制备方法
CN109363155A (zh) * 2018-11-19 2019-02-22 武汉市憧憬星元生物科技有限公司 一种野生菌功能型保健品制备方法及其制品
CN109287923A (zh) * 2018-12-03 2019-02-01 郭利芳 一种补气补血增强抵抗力功能型固体饮料
CN109464596A (zh) * 2018-12-06 2019-03-15 湖北文理学院 疏肝美颜中药组合物及中药制剂和应用
CN111012867A (zh) * 2019-12-23 2020-04-17 刘海波 一种虫草菌丝片及其制备方法
CN111467427B (zh) * 2020-03-12 2021-09-24 温州古木生物科技有限公司 一种中药组合物与其提取物及其在防治呼吸道病毒感染中的应用
CN111449274B (zh) * 2020-04-09 2022-02-15 福建中烟工业有限责任公司 一种人参提取物及其制备方法和应用
CN111657501A (zh) * 2020-05-14 2020-09-15 中国海洋大学 一种具有增强免疫力功能的牡蛎肽虫草菌丝体组合物及其应用
CN111743939A (zh) * 2020-08-18 2020-10-09 晋中学院 一种缓解化疗副作用的药膏及其制备方法和用途
CN113577240B (zh) * 2021-09-02 2024-01-30 翔宇药业股份有限公司 药物组合物及其制备方法和应用
CN114158729B (zh) * 2021-11-23 2024-01-26 中华全国供销合作总社济南果品研究院 含有西洋参提取物和黄精提取物的组合物、固体饮料
CN114425058B (zh) * 2022-03-22 2023-05-12 博奥生物集团有限公司 一种治疗鼻炎的中药组合物及其制备方法、药物和制剂
CN114788554A (zh) * 2022-04-06 2022-07-26 诺立(上海)生物工程有限公司 一种调节水产动物免疫力的营养组合物及其制备方法
CN114869949B (zh) * 2022-05-26 2023-06-20 山西黄河中药有限公司 一种用于治疗妇女产后疾病的药物组合物及其制备方法
CN114831309A (zh) * 2022-06-22 2022-08-02 杭州参友健康管理有限公司 一种灵芝西洋参组合物及其制备方法与应用
CN115177596A (zh) * 2022-07-14 2022-10-14 江中药业股份有限公司 一种参灵草直压片的制备方法及参灵草直压片
CN116035204B (zh) * 2022-12-20 2024-01-02 大连康芝源生物科技有限公司 一种食用菌提取物发酵型能量补充食品及制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101292742A (zh) * 2008-06-07 2008-10-29 江中药业股份有限公司 一种增强人体免疫功能的保健食品及其制备工艺
CN101999663A (zh) * 2010-09-17 2011-04-06 江中药业股份有限公司 中药组合物在制备缓解体力疲劳保健食品及药品中的应用
CN102228252A (zh) * 2010-09-17 2011-11-02 江中药业股份有限公司 中药组合物在制备提高缺氧耐受力保健食品及药品中的应用
CN102274259A (zh) * 2011-07-25 2011-12-14 江中药业股份有限公司 一种增强人体免疫功能的中药组合物
CN102274258A (zh) * 2011-07-25 2011-12-14 江中药业股份有限公司 一种增强人体免疫功能的中药组合物
CN102406163A (zh) * 2010-09-17 2012-04-11 江中药业股份有限公司 中药组合物在制备防治缓解体力疲劳保健食品或药品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1083386A (zh) * 1993-05-29 1994-03-09 广州奇星药厂 一种西洋参制剂及其制法
JPH08157388A (ja) 1994-12-06 1996-06-18 Nichinichi Seiyaku Kk 免疫調整剤
US6432454B1 (en) * 1997-12-12 2002-08-13 C. V. Technologies, Inc. Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
JP2001103933A (ja) 1999-10-07 2001-04-17 Tomoji Tanaka 霊芝胞子を入れた混合食品と飼料添加物
US6893641B2 (en) * 1999-10-12 2005-05-17 Chee-Keung Chung Ganoderma lucidum spores for treatment of autoimmune diseases
WO2001066122A2 (en) * 2000-03-07 2001-09-13 Mount Sinai School Of Medicine Of New York University Herbal remedies for treating allergies and asthma
US6551627B1 (en) * 2001-05-03 2003-04-22 Holomed Pharmaceuticals, Ltd. Medicinal herbal compounds for the prevention and treatment of diabetes
CN1413647A (zh) 2002-09-09 2003-04-30 凌一峰 一种根治艾滋病的纯中药制剂
CN1552437A (zh) * 2003-06-05 2004-12-08 靖 许 金水宝胶囊在制备治疗艾滋病的药物中的应用
JP2007045713A (ja) 2005-08-05 2007-02-22 Iskra Ind Co Ltd 霊芝胞子抽出物及び霊芝胞子製剤
CN100499994C (zh) * 2006-06-28 2009-06-17 中山大学 一种提升紫芝及紫芝孢子品质的方法
KR101266527B1 (ko) 2007-12-07 2013-05-27 주식회사한국신약 동충하초 균사체 추출물을 유효성분으로 함유하는 면역 억제용 조성물
CN101273780B (zh) * 2008-04-30 2011-04-20 福建农林大学 一种保健藤茶及其制备方法
CN101612182A (zh) * 2008-06-24 2009-12-30 龚卫东 一种降糖参花灵汤
CN101757158A (zh) * 2008-10-22 2010-06-30 曲继秀 一种西洋参玫瑰含片
CN101536968A (zh) * 2009-04-28 2009-09-23 济南天源玫瑰制品开发有限公司 玫瑰鲜花细胞液及其制备方法
KR101160488B1 (ko) 2009-06-22 2012-06-28 한국생명공학연구원 참나리 추출물을 함유하는 염증성 질환 및 천식의 예방 및 치료용 약학적 조성물
CN102283340A (zh) * 2010-06-21 2011-12-21 吉林省鼎健天然植物基地有限公司 营养强化蜂蜜
CN102526606A (zh) * 2010-12-16 2012-07-04 天津中敖生物科技有限公司 具有止咳化痰功能的中药组合物及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101292742A (zh) * 2008-06-07 2008-10-29 江中药业股份有限公司 一种增强人体免疫功能的保健食品及其制备工艺
CN101999663A (zh) * 2010-09-17 2011-04-06 江中药业股份有限公司 中药组合物在制备缓解体力疲劳保健食品及药品中的应用
CN102228252A (zh) * 2010-09-17 2011-11-02 江中药业股份有限公司 中药组合物在制备提高缺氧耐受力保健食品及药品中的应用
CN102406163A (zh) * 2010-09-17 2012-04-11 江中药业股份有限公司 中药组合物在制备防治缓解体力疲劳保健食品或药品中的应用
CN102274259A (zh) * 2011-07-25 2011-12-14 江中药业股份有限公司 一种增强人体免疫功能的中药组合物
CN102274258A (zh) * 2011-07-25 2011-12-14 江中药业股份有限公司 一种增强人体免疫功能的中药组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG, YANPING: "Research Status of Bulbus Lilii", CHINA PHARMACEUTICALS, vol. 19, no. 8, 31 December 2010 (2010-12-31), pages 88, XP008178947 *
TECHNICAL STANDARDS FOR TESTING AND ASSESSMENT OF HEALTH FOOD, 2003
WANG, YINGYI ET AL.: "Pharmacological Functions of Chemicals in Rhizoma Anemarrhenae", SCIENCE & TECHNOLOGY REVIEW, vol. 28, no. 12, 31 December 2010 (2010-12-31), pages 110 - 115, XP008178949 *
XU, AIJUAN ET AL.: "Research Development of Rhizoma Anemarrhenae", JOURNAL OF CHINESE MEDICINAL MATERIALS, vol. 31, no. 4, 30 April 2008 (2008-04-30), pages 624 - 628, XP008179001 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015199673A (ja) * 2014-04-04 2015-11-12 日本メナード化粧品株式会社 抗疲労剤
CN108041611A (zh) * 2017-12-25 2018-05-18 大连深蓝肽科技研发有限公司 一种提高男性性能力的保健食品及其制备方法
CN111617120A (zh) * 2020-06-03 2020-09-04 广州鹰远生物科技有限公司 一种人参虫草发酵提取物的制备方法
CN111617120B (zh) * 2020-06-03 2021-08-13 广州鹰远生物科技有限公司 一种人参虫草发酵提取物的制备方法
CN111955570A (zh) * 2020-09-17 2020-11-20 傅松涛 一种增强免疫力预防肿瘤的参白灵芝茶及其生产工艺
CN113455651A (zh) * 2021-07-09 2021-10-01 杨水祥 一种含有干细胞提取液的代谢和免疫增强及改善亚健康制剂
CN114698840A (zh) * 2022-04-06 2022-07-05 颖河(焦作)中药生物工程有限责任公司 一种用于增免的天然植物提取物及其生产工艺

Also Published As

Publication number Publication date
EP2949334A4 (en) 2016-06-01
CN109512931A (zh) 2019-03-26
CN109512925A (zh) 2019-03-26
RU2630056C2 (ru) 2017-09-05
EP2949334A1 (en) 2015-12-02
US9775868B2 (en) 2017-10-03
US20170368121A1 (en) 2017-12-28
CN109512926A (zh) 2019-03-26
EP2949334B1 (en) 2020-03-18
JP2015529670A (ja) 2015-10-08
MY179990A (en) 2020-11-19
RU2015113319A (ru) 2016-11-10
CN103656113A (zh) 2014-03-26
US10537600B2 (en) 2020-01-21
US20150265664A1 (en) 2015-09-24
EP3560507A1 (en) 2019-10-30
IN2015DN02833A (zh) 2015-09-11
CN109512924A (zh) 2019-03-26
EP3560507B1 (en) 2021-07-28
KR20160048021A (ko) 2016-05-03
JP6305407B2 (ja) 2018-04-04
KR101908381B1 (ko) 2018-12-19
ZA201502271B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
WO2014040396A1 (zh) 一种调节免疫的中药组合物及其制备方法
CN100548323C (zh) 一种由绞股蓝、西洋参和黄芪制成的药物组合物
CN111110824B (zh) 扶正救肺药物组合物及其应用
CN112007106A (zh) 一种辅助预防covid-19的发酵组合物及其制备方法
CN107156830B (zh) 一种增强免疫力的组合物、其制备方法和应用
TWI554277B (zh) 預防及治療非酒精性脂肪肝之醫藥組成物
CN103520318A (zh) 一种增强免疫功能的中药组合物及其制备方法
CN106309729B (zh) 一种调节慢性肝炎免疫功能的中药组合物
CN109568430B (zh) 一种免疫增强剂的制备方法和应用
CN106511915A (zh) 一种复方中药组合物在抑制皮肤黑色素瘤肺转移药物中的应用
WO2010037255A1 (zh) 一种人参绞股蓝复方制剂在制备调节血脂、血糖的药物中的用途
CN106581520B (zh) 一种治疗弥漫性肺间质纤维化肺气虚证的中药颗粒
CN111991436A (zh) 茅苍术水提物在制备预防、缓解和/或治疗高尿酸血症药物中的应用
TWI501771B (zh) 預防及治療肝纖維化之醫藥組成物
CN104740345B (zh) 治疗糖尿病的中药组合物及其制备方法
CN107927745B (zh) 一种中药保健食品组合物,其制备方法及其制剂
CN113101331B (zh) 一种百里香药茶及其制备方法和应用
CN115089689B (zh) 一种治疗痉挛性咳嗽的中药组合物及其制备方法、应用
CN109731076B (zh) 一种基于治未病理论的防治脾胃湿热证的药物或食疗制剂
WO2016110168A1 (zh) 20(R)-人参皂苷Rg3在制备缓解或/和治疗糖尿病药物或保健品中的应用及药物
CN113209261A (zh) 一种治疗放化疗后消化道复合症状群的药物组合物及其制备方法和用途
CN113908224A (zh) 一种具有免疫调节功能的中药组合物及其制备方法
CN114432376A (zh) 调血脂药物组合物及其制剂
KR20230149568A (ko) 고량강 추출물을 유효성분으로 포함하는 알러지성 호흡기 질환의 예방, 개선 또는 치료용 조성물
CN113908193A (zh) 药物组合物在治疗放射性肺炎中的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13837349

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015531424

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14428313

Country of ref document: US

Ref document number: 2013837349

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157008510

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201502109

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2015113319

Country of ref document: RU

Kind code of ref document: A